Transient elastography and fibrosis-4 index as predictors of hepatocellular carcinoma in hepatitis C virus patients with sustained virological response

Figure 1 Flow chart of inclusion of patients in the study and development of hepatocellular carcinoma. cACLD: Compensated advanced chronic liver disease; HCV: Hepatitis C virus; SVR: Sustained virological response; DAA: Direct-acting antivirals; HCC: Hepatocellular carcinoma; 1-year-EOT: One year after the end of treatment; TE: Transient elastography.

Figure 2 Kaplan Meier analysis regarding pre and 1-year-post-treatment liver stiffness measures and fibrosis-4 index score and hepatocellular carcinoma. A: Pre-treatment liver stiffness measure (LSM) (cut-off: 20 kPa); B: 1-year end of treatment LSM (cut-off: 20 kPa); C: Pre-treatment fibrosis-4 index (cut-off: 3.25); D: 1-year end of treatment fibrosis-4 index (cut-off: 3.25). EOT: End of treatment; LSM: Liver stiffness measure; FIB-4: Fibrosis-4; 1-year-EOT: One year after the end of treatment.